Compare Amphastar Pharmaceuticals Inc (AMPH) vs Mongodb Inc (MDB) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

MongoDB (MDB) trades at $342.08, down 5.73% in the latest session, amid mixed technical signals with a bullish moving average trend but overbought RSI readings. The company shows strong revenue growth, reaching $2.01B in 2025, with consistent earnings beats in recent quarters, though it remains unprofitable with a net margin of -1.12%. Recent news highlights AI-driven demand boosting database sales and raised FY2027 revenue guidance to $2.92–$2.96B.

Outlook remains positive with 82% analyst buy ratings and a $400.39 consensus target, offering ~17% upside. Key risks include ongoing profitability challenges, competitive pressures, and legal scrutiny over fiduciary duties. Revenue growth and AI adoption present opportunities, but investors should monitor margin improvement and execution against guidance.